ライフサイエンスコーパス: treatment with

1 Treatment with a Syk inhibitor significantly reduced renal al

2 Treatment with an Aha1 inhibitor, KU-177, dramatically reduce

3 Treatment with an antimalarial medication reduced parasitaemi

4 Treatment with basimglurant was overall well-tolerated.

5 Treatment with Ro 61-8048 decreased nicotine self-administrat

6 Treatment with specific GSK3 inhibitor (L803-mts), starting f

7 Treatment with tocilizumab in 13 subjects resulted in rapid d

8 T (RNA-CART123); (2) T-cell ablation with alemtuzumab after treatment with lentivirally transduced anti-CD123-4-1BB-CD3ze

9 ity also failed to up-regulate IFN-beta and TNF-alpha after treatment with DMXAA or the natural STING ligand cyclic GMP-A

10 stantially more cognitive difficulties up to 6 months after treatment with chemotherapy than do age-matched noncancer con

11 s were recorded at baseline and at 1, 2, and 4 months after treatment with DEX implants.

12 keys that had survived infection in the absence of or after treatment with candidate medical countermeasures.

13 Eleven (4%) of the 274 patients had PHD after treatment with (177)Lu-DOTATATE: 8 patients (2.9%) developed

14 V) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral ag

15 lls (CART123); and (3) T-cell ablation with rituximab after treatment with CD20-coexpressing CART123 (CART123-CD20).

16 he loss of dendritic outgrowth and number of synapses after treatment with a PERK activator, tunicamycin.

17 e aim of this study was to examine the associations between treatment with statins, renin-angiotensin system blockers, be

18 I imbalance, and histological damage are all ameliorated by treatment with NitroSynapsin, a new dual-action compound rela

19 of LLO, and this inhibitory effect was fully reversible by treatment with reducing agents.

20 c apoptosis in WT vs. CD-WT mice, which was prevented by co-treatment with the reactive oxygen species scavenger Tempol.

21 ycle kinase and reveals the potential for using combination treatment with CDK4/6 inhibitors and PD-1-PD-L1 immune checkp

22 Combined treatment with DHA and Physcion activates AMP-activated prote

23 tumor cells, the effects of which were overcome by combined treatment with osimertinib and SFK inhibitors.

24 ciated with an increased risk of virological failure during treatment with NNRTI-containing regimens.

25 e-mediated NET formation was further supported by exogenous treatment with autophagy inducer tamoxifen, which rescued the

26 monitored the transcriptional regulation of SNCA following treatment with different drugs known to regulate alpha-SYN ex

27 ted macular degeneration (AMD) who are being considered for treatment with antioxidants and zinc.

28 orinated pyrimidine and a platinum agent, followed by later treatment with taxanes and irinotecan, provides some benefit.

29 Systemic and ocular treatment with the TR antagonists NH-3 and 1-850 increased co

30 However, the ideal duration of treatment with interferon-free regimens, particularly in HIV-

31 were randomly assigned with equal likelihood to 12 weeks of treatment with escitalopram (10-20 mg/day), duloxetine (30-60

32 Assessments also gathered information on treatment with medications and confounding factors, such as s

33 In Necdin-KO pups, the genetic deletion of Slc6a4 or treatment with Fluoxetine, a 5-HT reuptake inhibitor, restore

34 propensity of acquiring mutations in response to vaccine or treatment with one or a cocktail of monoclonal antibodies.

35 itive early breast cancer were randomly assigned to receive treatment with perindopril, bisoprolol, or placebo (1:1:1) fo

36 omic outcomes in a subgroup of laser control eyes receiving treatment with intravitreal aflibercept injection.

37 entation reduces the rate of asthma exacerbations requiring treatment with systemic corticosteroids.

38 s R3230 adenocarcinoma tumors were allocated to RFA or sham treatment with or without a STAT3 inhibitor (S3I-201 or micel

39 DNA insertion were insensitive to AtRALF1, and simultaneous treatment with both AtRALF1 and CML38 proteins restored sensi

40 In a proof-of-concept setting systemic treatment with ustekinumab diminished imiquimod-induced infla

41 We found that treatment with the physiological NO donor S-nitrosoglutathion

42 of the Kalpha2-helix peptide, the present study showed that treatment with the Kalpha2 peptide fused with the TAT peptide

43 We have shown that treatment with the KATP channel agonist pinacidil increases s

44 phy (OCT) in eyes with NVAMD that were randomly assigned to treatment with either ranibizumab or bevacizumab.

45 rence in tumor burden or survival distributions compared to treatment with (+)-JQ1.

46 Prior to treatment with GAs to promote germination, the seeds were usu

47 tment would be associated with effective tumor control upon treatment with anti-PD-L1 therapy.

48 n develop uncontrollable movements known as dyskinesia upon treatment with L-DOPA.

49 ing viral replication following infection with FHV, whereas treatment with the KATP channel antagonist tolbutamide decrea

50 To determine whether treatment with mandibular advancement device, the main altern